Immutep’s American depositary receipts lost about $2.28 each in one session on March 13, 2026. That was an 83 percent drop. The cause: the company disclosed that an independent committee had recommended stopping its pivotal TACTI-004 Phase III trial for futility.
Now investors who held the stock have until July 6, 2026, to apply to lead the securities class action that followed. The court set that date.
What the lawsuit alleges
The class covers purchasers of Immutep ADRs between March 24, 2025, and March 12, 2026. The complaint says senior management spent that stretch talking up “strong operational progress” and “encouraging support from investigators” in the TACTI-004 study of eftilagimod alfa.
Behind the scenes, the suit claims, the company held internal data showing a materially higher risk that the trial would miss its primary endpoints. The plaintiffs say interim analyses contradicted the public optimism, yet positive projections kept coming through February 2026, just weeks before the trial was halted.
Then came March 13. In the complaint’s telling, the price correction wiped out most of shareholder value overnight.
The notice and the lead plaintiff role
The announcement came from SueWallSt, a firm that pitched it to pension funds, asset managers and other fiduciaries. It noted that Immutep had 1.4 billion ordinary shares outstanding as of June 30, 2025, and argued that institutions probably account for a large part of the affected class.
Joseph E. Levi, the attorney named in the release, said institutional investors “play a critical role” in these cases because their participation “ensures that the class is represented by sophisticated parties with the resources and incentive to maximize recovery.”
The lead plaintiff is the investor the court appoints to represent everyone in the class, usually the one with the largest documented losses. The role does not raise that person’s own payout. It does give direct oversight of how the case is run. Under the release’s terms, serving costs nothing out of pocket, because the case is handled on a contingency basis.
Investors who skip the deadline are not shut out of any recovery. The release says class members who do not apply can still take part without acting before July 6. A claim generally needs brokerage statements or trade confirmations showing purchase dates, share counts and prices paid, plus any later sales.
The firm says it has recovered hundreds of millions of dollars and has ranked among the ISS Top 50 for seven consecutive years.





